



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: **HM30181**

产品别名: **Encequidar; HM30181A**

生物活性:

| | | | | | |
|---|--|---|-----------|-----------|------------|
| Description | Encequidar (HM30181; HM30181A) is a potent and selective inhibitor of P-glycoprotein. | | | | |
| In Vitro | <p>Encequidar (HM30181; HM30181A) is shown to be approximately equipotent with the reference Pgp inhibitor tariquidar in inhibiting rhodamine 123 efflux from CCRF-CEM T cells (IC50, tariquidar: 8.2±2.0 nM, Encequidar (HM30181): 13.1±2.3 nM) [1].</p> <p>Encequidar (HM30181) shows a high selectivity for mP-gp and its potency is 20-50 times higher than that of tariquidar, another third generation P-gp inhibitor[2].</p> | | | | |
| In Vivo | <p>PET scans with the Pgp substrate (R)-[11C]NSC 657799 in FVB wild-type mice pretreated i.v. with Encequidar (HM30181) (10 or 21 mg/kg) fail to show significant increases in (R)-[11C]NSC 657799 brain uptake compared with vehicle treated animals[1].</p> <p>Encequidar (HM30181) inhibits P-gp mainly in the intestinal endothelium, which can be beneficial because pan-inhibition of P-gp, particularly in the brain, could lead to detrimental adverse events. Encequidar (HM30181) increases the oral bioavailability of co-administered NSC 125973 by more than 12 times in rats[2].</p> | | | | |
| Solvent&Solubility | In Vitro: DMSO : 6.9 mg/mL (10.02 mM; Need ultrasonic) | | | | |
| | Preparing Stock Solutions | <div>Solvent / Mass / Concentration</div> | 1 mg | 5 mg | 10 mg |
| | | 1 mM | 1.4519 mL | 7.2597 mL | 14.5195 mL |
| | | 5 mM | 0.2904 mL | 1.4519 mL | 2.9039 mL |
| | | 10 mM | 0.1452 mL | 0.7260 mL | 1.4519 mL |
| <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限: -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时, 请在 6 个月内使用, -20℃ 储存时, 请在 1 个月内使用。</p> | | | | | |
| References | <p>[1]. Bauer F, et al. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol. 2012 Dec 5;696(1-3):18-27.</p> <p>[2]. Kim TE, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014 Sep;78(3):556-64.</p> | | | | |
| 实验参考: | | | | | |
| Animal Administration | <p>Mice[1]</p> <p>Encequidar (HM30181) mesylate is dissolved in 5% aqueous glucose solution, containing 20 μL 0.01 M aq. HCl and injected at a volume of 4 mL/kg. Female FVB wild-type mice, aged 8-12 weeks weighing 24±4 g undergo (R)-[11C]NSC 657799 PET scans without and with i.v. pretreatment with cold Encequidar (HM30181). Animals are assigned to 5 groups (n=4 per group). One group is pretreated with HM30181 vehicle solution (5% aq. glucose solution containing 20 μL 0.01 M aq. HCl) at 60 min before start of the PET scan. The other groups are pretreated with either 10 mg/kg</p> | | | | |



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

| | |
|------------|---|
| | Encequidar (HM30181) at 10, 60 or 120 min before PET or with 21 mg/kg HM30181 at 10 min before PET[1]. |
| References | <p>[1]. Bauer F, et al. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol. 2012 Dec 5;696(1-3):18-27.</p> <p>[2]. Kim TE, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014 Sep;78(3):556-64.</p> |



源叶生物